Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences
Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022 Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI Additional results on the synergy of co-administering T-cell based vaccine candidate OVX836 with traditional antibody-based flu vaccines … [Read more…]
